Tyrosine kinase inhibitor for non-Small Cell Lung Cancer treatment

(NSCLC): EGFR (epidermal growth factor receptor) TKIs such as erlotinib (Tarceva), gefitinib (Iressa), and osimertinib (Tagrisso) are used for the treatment of NSCLC with specific EGFR mutations.